|
Jul 21
|
BioCryst to Report Second Quarter 2025 Financial Results on August 4
|
|
Jul 15
|
AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies
|
|
Jun 27
|
Sector Update: Health Care Stocks Retreat Late Afternoon
|
|
Jun 27
|
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
|
|
Jun 26
|
Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB
|
|
Jun 25
|
BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?
|
|
Jun 18
|
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?
|
|
Feb 24
|
BioCryst: Q4 Earnings Snapshot
|
|
Feb 24
|
BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
|
|
Feb 24
|
BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years
|
|
Feb 19
|
BioCryst to Present at Upcoming Investor Conferences
|
|
Feb 17
|
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Feb 12
|
BioCryst Launches ORLADEYO® (berotralstat) in Portugal
|
|
Feb 10
|
Exploring Three High Growth Tech Stocks In The United States
|
|
Feb 10
|
BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
|
|
Feb 10
|
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
|
|
Jan 14
|
BioCryst price target raised to $12 from $10 at Evercore ISI
|
|
Jan 10
|
Exploring High Growth Tech Stocks In January 2025
|
|
Jan 10
|
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
|